Cargando…

Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches

Acute myeloid leukemia (AML) is characterized by an increasing number of clonal myeloid blast cells which are incapable of differentiating into mature leukocytes. AML risk stratification is based on genetic background, which also serves as a means to identify the optimal treatment of individual pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dowling, Paul, Tierney, Ciara, Dunphy, Katie, Miettinen, Juho J., Heckman, Caroline A., Bazou, Despina, O’Gorman, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628952/ https://www.ncbi.nlm.nih.gov/pubmed/34842843 http://dx.doi.org/10.3390/proteomes9040042

Ejemplares similares

Proteomic and Metabolomic Analysis of Bone Marrow and Plasma from Patients with Extramedullary Multiple Myeloma Identifies Distinct Protein and Metabolite Signatures
por: Dunphy, Katie, et al.
Publicado: (2023)

Current Methods of Post-Translational Modification Analysis and Their Applications in Blood Cancers
por: Dunphy, Katie, et al.
Publicado: (2021)

Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients
por: Tierney, Ciara, et al.
Publicado: (2021)

Clinical Proteomics of Biofluids in Haematological Malignancies
por: Dunphy, Katie, et al.
Publicado: (2021)

S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma
por: Liu, Minxia, et al.
Publicado: (2021)

Using Proteomics Data to Identify Personalized Treatments in Multiple Myeloma: A Machine Learning Approach
por: Katsenou, Angeliki, et al.
Publicado: (2023)

P426: HDAC INHIBITORS RESTORE SENSITIVITY TO VENETOCLAX AND NAVITOCLAX IN AML CELLS RESULTING IN THE IRREVERSIBLE DNA DAMAGE
por: Khabusheva, Elmira, et al.
Publicado: (2023)

Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
por: Blum, Agnieszka, et al.
Publicado: (2018)

Marizomib: A novel therapeutic approach for the treatment of central nervous system myeloma
por: Bazou, Despina, et al.
Publicado: (2020)

Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients
por: Ting, Kay Reen, et al.
Publicado: (2017)

Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen
por: Miettinen, Juho J., et al.
Publicado: (2021)

Chromosomal rearrangements in acute myeloid leukemia (AML)
por: Belloni, E, et al.
Publicado: (2010)

New agents in acute myeloid leukemia (AML)
por: Park, Silvia, et al.
Publicado: (2020)

AngioCRIME in Acute Myeloid Leukemia (AML)
por: Macintyre, Elizabeth
Publicado: (2017)

DNA Methylation Signatures Predict Cytogenetic Subtype and Outcome in Pediatric Acute Myeloid Leukemia (AML)
por: Krali, Olga, et al.
Publicado: (2021)

Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types
por: Majumder, Muntasir M., et al.
Publicado: (2020)

Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with BCR::ABL1 from Chronic Myeloid Leukemia (CML) in Blast Crisis
por: Boucher, Lara, et al.
Publicado: (2023)

An immunity and pyroptosis gene-pair signature predicts overall survival in acute myeloid leukemia
por: Kong, Weikaixin, et al.
Publicado: (2022)

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)
por: Assouline, Sarit, et al.
Publicado: (2012)

Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?
por: Webersinke, G, et al.
Publicado: (2014)

Modelling acute myeloid leukemia (AML): What’s new? A transition from the classical to the modern
por: Dozzo, Annachiara, et al.
Publicado: (2022)

A Prognostic Autophagy-Related Long Non-coding RNA (ARlncRNA) Signature in Acute Myeloid Leukemia (AML)
por: Zhao, Chunxia, et al.
Publicado: (2021)

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
por: Yilmaz, Musa, et al.
Publicado: (2019)

New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML)
por: Chen, Jing, et al.
Publicado: (2020)

Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?
por: Guolo, Fabio, et al.
Publicado: (2022)

Choosing the Right Cell Line for Acute Myeloid Leukemia (AML) Research
por: Skopek, Rafał, et al.
Publicado: (2023)

Route Determination of Sulfur Mustard Using Nontargeted Chemical Attribution Signature Screening
por: Höjer Holmgren, Karin, et al.
Publicado: (2021)

Acute Myeloid Leukemia (AML) with Erythroid Predominance Exhibits Clinical and Molecular Characteristics that Differ from Other Types of AML
por: Zuo, Zhuang, et al.
Publicado: (2012)

Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
por: Hofmann, Susanne, et al.
Publicado: (2019)

Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches
por: Winer, Eric S., et al.
Publicado: (2019)

Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes
por: Matre, Polina, et al.
Publicado: (2016)

Integrated N- and O-Glycomics of Acute Myeloid Leukemia (AML) Cell Lines
por: Blöchl, Constantin, et al.
Publicado: (2021)

Chemotherapy as Treatment for Acute Myeloid Leukemia (AML)-Induced Facial Nerve Palsy
por: Fana, Michael, et al.
Publicado: (2022)

A new approach in acute myeloid leukemia (AML): Samatya-predicting score
por: Serin, Istemi, et al.
Publicado: (2022)

Context-specific effects of NOX4 inactivation in acute myeloid leukemia (AML)
por: Demircan, Muhammed Burak, et al.
Publicado: (2022)

The Question of Survival or Death: What Is the Role of Autophagy in Acute Myeloid Leukemia (AML)?
por: Haghi, Atousa, et al.
Publicado: (2022)

P478: MOLECULAR CHARACTERIZATION OF EXTRAMEDULLARY LOCALIZATIONS IN ACUTE MYELOID LEUKEMIA (AML)
por: Silvestrini, Giorgia, et al.
Publicado: (2023)

P1686: LONG-TERM COMORBIDITY AND HEALTH PROBLEMS IN ACUTE MYELOID LEUKEMIA (AML) SURVIVORS: AN INTERNATIONAL AML SURVIVORSHIP STUDY
por: Efficace, Fabio, et al.
Publicado: (2023)

Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML)
por: Tang, Ruoping, et al.
Publicado: (2008)

Treatment of relapsed undifferentiated acute myeloid leukemia (AML-M0) with Ayurvedic therapy
por: Prakash, Balendu
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_9dkj44f4ou1lsboah064qn8qbb